{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T08:58:47Z","timestamp":1790326727193,"version":"4.1.0"},"reference-count":77,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T00:00:00Z","timestamp":1572480000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acta Psychiatr Scand"],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Clozapine is the only approved strategy for treatment\u2010resistant schizophrenia, although it is highly underutilized. We aim to generate practical and actionable evidence\u2010based recommendations for the use of this drug considering prescription barriers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>Narrative review.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A consistent body of evidence supports the efficacy of clozapine reducing morbidity and mortality in schizophrenia. The main obstacles to its use are the lack of experience by prescribers and perceived treatment burden. Systematic screening of eligibility, utilization of available resources for consultation, developing a professional network with other stakeholders, as well as optimizing how clozapine is presented to patients is discussed. Furthermore, specific evidence\u2010based recommendations for initiation, maintenance, and safety monitoring with clozapine are provided.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Clozapine prescription is one of the areas in psychiatry with the greatest mismatch between efficacy and utilization in clinical practice. Although multiple barriers to the use of clozapine exist, some of these may be overcome by updates of routine clinical practice.<\/jats:p><\/jats:sec>","DOI":"10.1111\/acps.13111","type":"journal-article","created":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T17:02:26Z","timestamp":1570813346000},"page":"178-189","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["How and when to use clozapine"],"prefix":"10.1111","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0056-4135","authenticated-orcid":false,"given":"J. M.","family":"Rubio","sequence":"first","affiliation":[{"name":"Donald and Barbara Zucker School of Medicine Hofstra\/Northwell Glen Oaks NY USA"},{"name":"Feinstein Institute for Medical Research, Northwell Health Glen Oaks NY USA"},{"name":"The Zucker Hillside Hospital \u2013 Northwell Health Glen Oaks NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"Kane","sequence":"additional","affiliation":[{"name":"Donald and Barbara Zucker School of Medicine Hofstra\/Northwell Glen Oaks NY USA"},{"name":"Feinstein Institute for Medical Research, Northwell Health Glen Oaks NY USA"},{"name":"The Zucker Hillside Hospital \u2013 Northwell Health Glen Oaks NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,10,31]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2017.16121358"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60239-6"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2016.16050503"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800330013001"},{"key":"e_1_2_9_6_1","unstructured":"Novartis.Clozaril (clozapine)[package insert]. U.S. Food and Drug Administration.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/019758s062lbl.pdf. Accessed August 12 2019."},{"key":"e_1_2_9_7_1","unstructured":"Leponex (clozapine) [European Commission final decision].European Medicines Agency.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/leponex. EC decision date November 12 2002. Accessed August 12 2019."},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbp116"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.3109\/15622975.2012.696143"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12742"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(15)00575-1"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.0624"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201600041"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/eip.12683"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2018.05.046"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjb.2018.67"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2011.01710.x"},{"key":"e_1_2_9_18_1","doi-asserted-by":"crossref","DOI":"10.1017\/9781108553575","volume-title":"The clozapine handbook","author":"Meyer J","year":"2019"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31135-3"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2015.2955"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2015.2966"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.1322"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2015.15030332"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbj067"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2007.04.043"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.115.177261"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2019.1702"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2017.16091097"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.1.82"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2004.05.015"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199903113401003"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2003.029868"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.3109\/15622975.2015.1009163"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181e7810a"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbl003"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/15504263.2011.570118"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.52.11.1510"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.17r11852"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/0893-133X(94)00069-C"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199106000-00022"},{"key":"e_1_2_9_41_1","unstructured":"LoveR KellyD FreudenreichO MacKenzieS.Clozapine Underutilization: Addressing the Barriers. Alexandria VA National Association of State Mental Health Program Directors. September 2016.https:\/\/www.nasmhpd.org\/sites\/default\/files\/Assessment%201_Clozapine%20Underutilization.pdf. Accessed August 12 2019."},{"key":"e_1_2_9_42_1","unstructured":"Leading Change Adding Value Team.The \u2018Getting Clozapine Right\u2019 initiative at Northern Devon Healthcare NHS Trust. April 2019."},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12193"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000188"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n1012"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1192\/pb.24.12.450"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1177\/2045125314566808"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201300180"},{"key":"e_1_2_9_49_1","unstructured":"World Health Organization.Mental Health and Prisons.https:\/\/www.who.int\/mental_health\/policy\/mh_in_prison.pdf. Accessed August 12 2019."},{"key":"e_1_2_9_50_1","unstructured":"Treatment Advocacy Center.The Treatment of Persons with Mental Illness in Prisons and Jails: A State Survey. April 2014.https:\/\/www.treatmentadvocacycenter.org\/storage\/documents\/treatment-behind-bars\/treatment-behind-bars.pdf"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291716002014"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.15032su1"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.13m08946"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12241"},{"key":"e_1_2_9_55_1","first-page":"231","article-title":"Clozapine and norclozapine plasma concentrations and clinical response of treatment\u2010refractory schizophrenic patients","volume":"148","author":"Perry PJ","year":"1991","journal-title":"Am J Psychiatry"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.152.2.179"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.151.12.1744"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2014.13060787"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4426"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12233"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psym.2018.07.010"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1017\/S003329171100105X"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.153.12.1579"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2015.11.006"},{"key":"e_1_2_9_65_1","unstructured":"Cephalon.Provigil[modafinil] FDA package insert. Last reviewed 2007 Accessed 2019."},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.07r03982"},{"key":"e_1_2_9_67_1","first-page":"CD009555","article-title":"Clozapine dose for schizophrenia","volume":"6","author":"Subramanian S","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n1005"},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-016-0311-1"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2018.12.011"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0608388"},{"key":"e_1_2_9_72_1","doi-asserted-by":"publisher","DOI":"10.1177\/0004867417720516"},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000000715"},{"key":"e_1_2_9_74_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41397-017-0004-2"},{"key":"e_1_2_9_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(01)01000-2"},{"key":"e_1_2_9_76_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.1220"},{"key":"e_1_2_9_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2009.05.007"},{"key":"e_1_2_9_78_1","first-page":"27","article-title":"Training in a clozapine clinic for psychiatry residents: a plea and suggestions for implementation","volume":"37","author":"Freudenreich O","year":"2013","journal-title":"Acad Psychiatry J Am Assoc Dir Psychiatr Resid Train Assoc Acad Psychiatry"}],"container-title":["Acta Psychiatrica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Facps.13111","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/acps.13111","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/acps.13111","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/acps.13111","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T19:32:43Z","timestamp":1694028763000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/acps.13111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,31]]},"references-count":77,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["10.1111\/acps.13111"],"URL":"https:\/\/doi.org\/10.1111\/acps.13111","archive":["Portico"],"relation":{},"ISSN":["0001-690X","1600-0447"],"issn-type":[{"value":"0001-690X","type":"print"},{"value":"1600-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,31]]},"assertion":[{"value":"2019-10-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}